Paclitaxel in advanced non-small cell lung cancer: An alternative high- dose weekly schedule

Chest

Volumn 117, Issue 4 SUPPL. 1, 2000, Pages 152S-155S

  Akerley III, Wallace ^a,b  

^a Brown University Oncology Group   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Dose intensity; Maximum tolerated dose; Non small cell lung cancer; Paclitaxel; Platelets

Indexed keywords

PACLITAXEL;

ADVANCED CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MAXIMUM ALLOWABLE CONCENTRATION; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0033995839     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Chang AY, Kim K, Glick J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85:388-394
2. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated non-small cell lung cancer. J Natl Cancer Inst 1993; 85:384-388
3. Wiernik P, Schwartz E, Einzig A, et al. Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5:1232-1239
4. Donehower R, Rowinsky E, Grochow L, et al. Phase I trial of Taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71:1171-1177
5. Holmes FA, Walters RS, Therialt RL, et al. Phase II trial of Taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 1991; 17:1797-1805
6. Arbuck S, Canetta R, Onetto O, et al. Current dosage and schedule issues in the development of paclitaxel. Semin Oncol 1993; 20(suppl 3):31-39
7. Nabholtz J, Gelman K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14:1858-1867
8. Bonomi P, Kim K, Chang A, et al. Phase II trial comparing etoposide, cisplatin versus Taxol, cisplatin, G-CSF versus Taxol, cisplatin in advanced non-small cell lung cancer [abstract 1145]: an ECOG trial. Proc Am Soc Clin Oncol 1996; 15:382
9. Eisenhauer E, Huinink W, Swenerton K, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654
10. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981; 91:479-487
11. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982; 94:688-696
12. Choy H, Akerley W, Safarin H, et al. Phase I trial of paclitaxel and thoracic radiation in NSCLC. J Clin Oncol 1994; 12: 2682-2686
13. Glantz M, Choy H, Kearns C, et al. Phase I study of weekly outpatient astrocytomas. J Clin Oncol 1996; 14:600-609
14. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced cell lung cancer. J Clin Oncol 1998; 16:153-158
15. Kearns C, Egorin M. Considerations regarding the less-than expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997; 24(suppl 2):91-96